Daily non-political popular news in brief.

Combination therapy reduces exacerbations in severe COPD

For patients with severe chronic obstructive pulmonary disease (COPD), combining a long-acting bronchodilator with an inhaled corticosteroid reduced the number of exacerbations by 35 percent.

Read more »

Keywords: combination, therapy, exacerbations, severe, copd, exacerbation

« Previous | Next »

Similar news on "Combination therapy reduces exacerbations in severe COPD":

1. New therapy reduces mortality in patients with severe COPD
   12-28-2007 · EurekAlert!
   Patients with severe COPD may benefit more from therapy that combines salmeterol and fluticasone than treatment with tiotropium, according to results from a long-term, multi-center study, "Investigating New Standards for Prophylaxis in Reducing Exacerbations" that directly compared the two therapies.
   Similar news · Read more »
   
2. Combination therapy stops loss of kidney function in rare genetic disease
   07-25-2007 · EurekAlert!
   A combination of two types of blood pressure-lowering drugs -- an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) with agalsidase-beta (Fabrazyme, Genzyme Corporation, Cambridge, Mass.) -- is the first treatment shown to stop progressive loss of kidney function in patients with severe kidney involvement due to the rare genetic disorder Fabry disease, reports a study in the September Journal of the American Society of Nephrology.
   Similar news · Read more »
   
3. Study finds COPD patients taking inhaled steroids are at greater risk for severe pneumonia
   07-16-2007 · EurekAlert!
   Patients with Chronic Obstructive Pulmonary Disease (COPD) are increasingly being prescribed inhaled corticosteroids to control exacerbations of the disease, but a new study finds that the anti-inflammatory drugs increase the chances that these patients will be hospitalized for pneumonia.
   Similar news · Read more »
   
4. Tracing agent, ultrasound combo helps test cancer therapy's effectiveness
   01-08-2007 · UT Southwestern Medical Center
   An inexpensive tracing agent used in combination with ultrasound can pinpoint how effectively drugs targeting pancreatic cancer work, researchers at UT Southwestern Medical Center have demonstrated for the first time.
   Similar news · Read more »
   
5. Scientists follow familiar TRAIL to new cancer therapy
   07-09-2007 · EurekAlert!
   A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials. The research, published in the July issue of the journal Cancer Cell, published by Cell Press, provides a pharmacological method for enhancing the potency and effectiveness of a tumor necrosis factor death receptor ligand against a variety of human cancers.
   Similar news · Read more »
   
6. Promising drug combination may help those with ocular melanoma that has spread
   09-04-2007 · EurekAlert!
   A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.
   Similar news · Read more »
   
7. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
   01-31-2008 · EurekAlert!
   Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.
   Similar news · Read more »
   
8. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
   10-03-2007 · EurekAlert!
   UT Southwestern Medical Center has been selected to take part in an $11.5 million multicenter clinical trial that is examining the effectiveness of induced hypothermia as a therapy for brain swelling in children who have suffered severe traumatic brain injuries.
   Similar news · Read more »
   
9. Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
   02-02-2008 · EurekAlert!
   One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.
   Similar news · Read more »
   
10. NEJM report on cardiac emergency therapy finds single medication effective vs. combination drugs
    11-22-2006 · EurekAlert!
    A study published in the New England Journal of Medicine led by Columbia University Medical Center and New York-Presbyterian Hospital researchers showed that an anti-clotting agent called bivalirudin, when used by itself to treat acute coronary syndromes, reduced the risk of major bleeding, a key risk for mortality, by 47 percent compared with the standard combination drugs. The medication was found to be equally as effective as the combination of injectable blood thinners traditionally used.
    Similar news · Read more »